Is the Synthetic Biology Market growing now?
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
Yes, the Synthetic Biology Market is growing now, but the growth is concentrated in tools, therapeutics and a relatively small number of industrial applications that have already found workable economics.
The headline market size is less useful than it looks. Credible 2026 estimates range from roughly $19 billion to $32 billion, largely because different researchers draw the boundary around synthetic biology in very different places.
The science is moving faster than the financing cycle. Sequencing, DNA synthesis, CRISPR, automation and AI keep making biological design easier, even though venture funding is still far below its 2021 peak.
Funding has reopened, but not broadly. In our stricter 12-month pure-play sample, just 19 disclosed equity rounds raised $1.01 billion, and the three largest deals captured 68.4% of the total.
The capital that is available has a clear preference. Therapeutics, computational biology and enabling infrastructure absorbed 91.6% of the funding we tracked, while food and materials attracted very little.
The cleanest commercial growth is in picks-and-shovels businesses. Twist Bioscience grew quarterly revenue 23% year over year while gene shipments jumped 56%, showing that more biological work is actually moving through the system.
AI is already improving some laboratory economics, but it has not solved the industrial problem. Automated experimentation can reduce the cost of finding a better biological process; it cannot remove the cost of fermentation vessels, purification, feedstocks or underused plants.
Industrial scale is no longer hypothetical. Qore's 66,000-tonne bio-based BDO plant proves engineered biology can run at meaningful commercial volume, but the fact that projects of this size are still exceptional shows how early the manufacturing layer remains.
Food fermentation captures the contradiction well: products and facilities are advancing while private funding is falling. Investors now want proof on cost per kilogram, plant utilization and repeat demand, not just technical feasibility.
The market is therefore moving from a technology story into a commercialization filter. Synthetic biology is growing, but the winners increasingly need either high-value economics, a tool that serves many programs, or a clear route into an existing market with customers already waiting.
This market map, featured in our synthetic biology market deck, highlights top companies and startups in the synthetic biology market
How big is the synthetic biology market today, really?
We should treat synthetic biology as a roughly $20 billion to $30 billion market today, with any more precise number giving false confidence.
Current market estimates vary unusually widely. Grand View Research puts the market at about $22.1 billion in 2026, 360iResearch at roughly $19.4 billion, Global Market Insights at about $30.1 billion, and The Business Research Company at around $32 billion. A spread of more than $12 billion for the same year tells us immediately that “synthetic biology market” is not measured consistently.
The reason is simple. Some researchers mostly count synthetic DNA, enzymes, genome-editing tools and bioprocessing. Others also pull in therapeutics, industrial biotechnology, engineered ingredients and downstream products. The OECD has explicitly pointed out that synthetic biology still lacks a single globally accepted definition.
For this article, the useful question is therefore whether economic activity around engineered biology is expanding across the businesses where synthetic biology is central. We care about revenue, funding, customers, manufacturing capacity and commercial products much more than a market-research CAGR.
Despite their different definitions, the major commercial estimates agree on one thing: spending is moving upward. Their implied annual growth rates generally sit in the low-to-high teens. That gives us a useful starting point, although the harder evidence comes from what companies and customers are actually doing.
Why does synthetic biology look alive in the lab but weak in the market?
Synthetic biology today is advancing much faster scientifically than financially, and that gap explains much of the confusion around whether the market is growing.
The technology has become dramatically easier to work with. The OECD estimates that sequencing costs have fallen roughly a millionfold over two decades, while DNA synthesis costs have dropped roughly a thousandfold. CRISPR, lab automation, cheaper sequencing and AI have also shortened the time between designing a biological system and testing it.
The capital cycle went in the opposite direction after the previous boom. OECD data show global synthetic biology venture investment rising above $20 billion at the 2021 peak and falling to just over $5 billion by 2023 under its definition. That is roughly a 75% contraction in two years.
Those two trajectories can coexist. Scientists can run more experiments, design better proteins and manipulate cells more precisely while investors become much stricter about which companies deserve financing. Several high-profile companies from the earlier cycle also learned that impressive biological engineering does not automatically produce attractive manufacturing economics.
That is where the market sits today. The underlying capability keeps improving. The business models are being forced to catch up.
If you want more recent data on this point, please see our latest synthetic biology market report.
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Is synthetic biology funding actually coming back?
Yes, synthetic biology funding is coming back from the bottom of the cycle, although the rebound is narrow and still far below the 2021 peak.
SynBioBeta's broader industry dataset shows venture investment reaching $12.2 billion in 2024, up from $10.7 billion in 2023. Its longer history shows the familiar shape: a large surge beginning around 2020, a peak in 2021, a sharp cooling through 2022 and 2023, then an initial rebound.
We get a much smaller number when we apply a stricter definition. Our review of publicly disclosed equity rounds by pure-play synthetic biology companies found 19 deals worth $1.01 billion in the 12 months ending in July 2026. We excluded conventional biotech, basic GMOs, traditional fermentation, grants, debt, acquisitions and companies where synthetic biology was only a secondary activity.
The difference between $12.2 billion in SynBioBeta's broad dataset and $1.01 billion in our narrower sample is useful. A large part of the debate about whether synthetic biology funding is “back” comes down to taxonomy. Once adjacent biotech is stripped away, visible pure-play funding looks much thinner.
Still, companies are raising meaningful rounds. NewLimit recently closed a $435 million Series C around epigenetic reprogramming medicines. Profluent raised $106 million for AI-designed programmable biology. Strand Therapeutics raised $153 million for programmable mRNA. Ansa Biotechnologies raised $54.4 million to expand enzymatic DNA synthesis.
So the financing market has reopened for companies with unusually strong technology or economics. Broad easy money has yet to return.
Are investors funding the whole synthetic biology market or just a few winners?
Current synthetic biology funding is heavily concentrated in a few winners, so the $1.01 billion headline gives too flattering a picture of financing conditions for the typical startup.
In our 19-round sample, NewLimit's $435 million financing alone represented 42.9% of all disclosed capital. The three biggest deals captured 68.4%, and the ten biggest captured 92.5%. Removing NewLimit takes the total from $1.01 billion to $579 million.
The average round was $53.4 million, which initially looks healthy. The median was only $19 million. Six of the nineteen deals reached $50 million or more, and those six absorbed 79.2% of all the money.
The gap becomes even clearer when we remove every round above $50 million. Only $210.6 million remains across the rest of the sample.
That concentration is probably the best way to describe today's funding environment. Exceptional synthetic biology companies can still access very deep pools of capital. An ordinary company faces a much tighter market.
| Funding measure | Latest 12-month pure-play sample | What it tells us |
|---|---|---|
| Disclosed equity rounds | 19 | Deal flow remains modest |
| Total disclosed funding | $1.01B | Large headline total |
| Largest round | $435M | One company captured 42.9% |
| Top three share | 68.4% | Most capital sits at the top |
| Median round | $19M | Typical funding is much smaller than the average |
| Funding excluding rounds above $50M | $210.6M | Ordinary financing conditions remain tight |
If you want more recent data on this point, please see our latest synthetic biology market report.
This chart, featured in our synthetic biology market deck, illustrates yearly VC funding for synthetic biology startups
What parts of synthetic biology are getting funded now?
Right now, synthetic biology money is clustering around therapeutics, AI-enabled biological design and enabling infrastructure.
Our latest pure-play funding sample makes the split unusually clear. Synthetic biology therapeutics produced only four of nineteen deals, yet those four companies raised $664.1 million, or 65.5% of all the capital we tracked.
Software and computational biology came next. Profluent, Scala Biodesign, Scindo and Pumpkinseed together attracted $147.4 million. These companies all connect computation to a physical biological output such as genome editors, proteins, enzymes or biological datasets.
Biofoundry and enabling platforms raised another $117.7 million. Ansa is expanding enzymatic DNA manufacturing, bit.bio programs human cells, and Cauldron Ferm is trying to improve the economics of industrial fermentation.
Materials had a much colder reception. Three materials-platform deals raised only $18.5 million combined. Food was thinner again: StrainX Bioworks was the only qualifying pure-play food deal in our 12-month sample, at $13 million.
Taken together, therapeutics, design software and biofoundry infrastructure captured 91.6% of disclosed capital. Investors currently seem happiest when synthetic biology leads to a high-value medicine or when a company sells tools that make many other biological programs faster. Consumer products and commodity-like materials still have a much harder financing story.
Are synthetic biology tools actually selling more today?
Yes, synthetic biology tools are selling more today, and Twist Bioscience's latest numbers give us some of the clearest commercial evidence in the market.
Twist reported $118.4 million of revenue in its latest fiscal quarter, up 23% from a year earlier and marking its fourteenth consecutive quarter of sequential revenue growth. DNA Synthesis and Protein Solutions grew even faster, rising 39% to $56.6 million.
The volume underneath that revenue is especially useful. Twist shipped about 369,000 genes during the quarter, up from roughly 237,000 a year earlier. That is a 56% increase in physical gene shipments. The number of purchasing customers also rose from about 2,484 to 2,664.
The growth is coming from real research activity across several customer groups. Therapeutics revenue increased from $27 million to $40.4 million year over year, while academic and government revenue also rose. Twist now says it serves more than 3,800 customers annually.
Margins have held up as volume increased. Gross margin was 52.8% in the latest quarter, and management lifted full-year revenue guidance to $456 million to $457 million while continuing to target adjusted EBITDA breakeven.
This is one of the cleanest areas of synthetic biology today. More biological design creates more demand for DNA, genes, libraries and protein tools regardless of which downstream startup eventually wins. The picks-and-shovels layer is already behaving like a real growth business.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Is AI making synthetic biology cheaper already?
AI is already cutting experimental costs in synthetic biology in controlled workflows; manufacturing economics remain a separate bottleneck.
The clearest example so far comes from work between OpenAI and Ginkgo Bioworks. GPT-5 was connected to an automated laboratory and allowed to iteratively optimize cell-free protein synthesis. Across six rounds, the system explored more than 36,000 experimental conditions.
The resulting formulation cut protein-production costs by 40% relative to the previous baseline and reduced reagent costs by 57%. The interesting part is the loop itself: the model proposed experiments, physical equipment ran them, the results came back, and the next experiments were chosen from the new data.
That approach attacks a very old bottleneck in biology. Computational models can generate enormous numbers of possible sequences or conditions, but somebody still has to test them in the physical world. Ginkgo's latest update says its Nebula autonomous laboratory now has more than 100 robots capable of running experiments around the clock.
Investment is following the same direction. Profluent is using generative models to create genome editors and proteins, NewLimit combines AI with large-scale cellular screening to find reprogramming payloads, and several smaller companies are building software around protein or enzyme design.
The claim should stay narrow. AI is clearly making parts of biological R&D faster and cheaper today. A cheaper experiment does not make a $300 million manufacturing plant disappear.
If you want more recent data on this point, please see our latest synthetic biology market report.
Can synthetic biology actually work at industrial scale?
Yes, synthetic biology can work at industrial scale; the number of proven commercial plants is still small.
Qore gives us a useful benchmark. The Cargill and HELM joint venture started commercial production at a roughly $300 million facility in Iowa in 2025. The plant is designed to produce 66,000 metric tons a year of QIRA, a bio-based version of 1,4-butanediol produced using technology licensed from Genomatica.
That is serious industrial capacity. BDO already has a large established market in spandex, footwear, automotive parts, electronics and other materials. QIRA can enter those supply chains as a replacement for fossil-derived BDO, and BASF has signed a long-term supply agreement. At full capacity, the Iowa plant alone represents roughly 2% of global BDO demand.
Food biomanufacturing is also moving beyond tiny demonstration facilities. The Good Food Institute found new commercial-scale fermentation facilities opening across several countries in 2025. Pow.Bio and Bühler also demonstrated continuous production of high-value dairy proteins at 3,000-liter scale, reporting more than threefold productivity gains and a 50% cost reduction in that project.
Still, commercial plants remain noteworthy events. If industrial synthetic biology were already mature, a 66,000-tonne facility would look routine. Today it remains one of the examples we point to when asking whether the technology can scale.
The evidence supports industrial viability in selected cases. It does not yet show that biological manufacturing can economically replace conventional production across a wide range of commodities.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Are synthetic biology chemicals and materials becoming real businesses?
Synthetic biology chemicals and materials are becoming real businesses, although the economics still look considerably tougher than the science.
QIRA shows one model that makes sense: use engineered biology to manufacture an existing chemical with known specifications and established demand. Customers already know what BDO does. They can substitute a bio-based version inside products they already sell without creating a new consumer category from scratch.
LanzaTech shows how much harder the economics can become even after commercial deployment. In its latest reported quarter, revenue rose from $9.5 million to $12 million year over year. Yet CarbonSmart product sales were essentially flat at about $4.1 million, and the biggest revenue increase came from engineering and other services, which rose from $1.8 million to $6.4 million.
LanzaTech has made major progress on costs. Its adjusted EBITDA loss narrowed from $30.5 million to $7.9 million year over year after a large restructuring. That is a substantial improvement, although it also shows how much work was required to get the cost base closer to the current level of revenue.
Venture investors appear to have noticed the same problem. As seen above, materials companies represented three of the nineteen deals in our pure-play sample yet attracted just 1.8% of the money.
The better industrial opportunities today look increasingly specific: a molecule with an existing market, a process with measurable cost or supply-chain advantages, and a realistic path to high plant utilization. Broad promises about “replacing petrochemicals with biology” carry much less weight than they did during the previous funding cycle.
If you want more recent data on this point, please see our latest synthetic biology market report.
Is precision fermentation for food still growing?
Precision fermentation for food is still progressing commercially, while private funding has moved sharply backward.
The Good Food Institute counted more than 163 specialized fermentation companies in 2025. Products continued moving into actual distribution: The EVERY Company put fermentation-derived egg protein into Walmart, Remilk entered cafes and restaurants through a dairy partnership, and other companies launched dairy proteins and functional ingredients across several markets.
Infrastructure has also improved. New production facilities opened, companies tested alternative feedstocks at commercially relevant scales, and continuous-fermentation systems demonstrated better productivity. Those are useful signs of operating progress.
Investors are much less enthusiastic. GFI calculates that fermentation-focused companies raised $357 million in 2025, down from $632 million the year before. That is a drop of roughly 44%. The largest reported private financing was only $55 million.
The funding decline is especially striking because it happened while products and facilities were still advancing. Investors have moved on to the tougher questions: cost per kilogram, purification expense, plant utilization, customer demand and the route to price parity.
Precision fermentation gives us one of the clearest examples of an industry that can grow operationally while shrinking financially. More can be manufactured today, yet companies still have to prove that enough of it can be sold at attractive economics.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Why are synthetic biology therapeutics getting most of the big checks?
Current synthetic biology funding clearly favors therapeutics because drug economics can absorb long R&D cycles and low-volume manufacturing far better than commodity products can.
Our funding data are unusually decisive here. Four therapeutic companies captured $664.1 million, or 65.5% of all the capital in the 19-company sample. The average therapeutic round was about $166 million.
NewLimit dominates that group with its $435 million Series C. The company is developing epigenetic reprogramming medicines and says its first program is moving toward human trials. NewLimit also reported that it tested more reprogramming payloads in 2025 than during 2022 through 2024 combined, giving investors evidence of improving experimental throughput as well as a therapeutic story.
Strand Therapeutics raised $153 million around programmable mRNA designed to control where therapeutic payloads are expressed. Think Bioscience added $55 million for a platform combining synthetic biology, enzymology and computational chemistry. Telum Therapeutics raised $21.1 million around protein-based antimicrobials.
As pointed out above, NewLimit alone accounts for 42.9% of our total pure-play funding sample. So we should avoid treating therapeutics as a broad-based funding boom. Still, the preference is obvious.
A successful drug can be worth billions while requiring relatively little material to manufacture. A bio-based commodity may need a huge plant to compete for a few dollars of value per kilogram. Investors currently prefer the first economic equation.
Which public synthetic biology companies are actually growing?
Public synthetic biology companies are moving in very different directions today: Twist is growing quickly, LanzaTech is improving from a weak base, and Ginkgo is still shrinking.
Twist currently gives us the strongest commercial picture. Beyond its 23% revenue growth, gene shipments jumped 56% year over year. That tells us the company is processing materially more biological work, rather than simply collecting higher prices from the same volume.
LanzaTech's latest quarter was better than a year earlier. Revenue increased about 27% to $12 million and its adjusted EBITDA loss narrowed sharply. The mix still deserves caution: engineering services drove most of the revenue increase, while CarbonSmart product sales barely moved.
Ginkgo is the clearest negative case. Its latest quarterly revenue fell from $39.1 million to $20.2 million, a 48% decline, mainly because the company has been rationalizing programs during its restructuring. Its adjusted EBITDA loss also widened to $36 million.
Yet Ginkgo's underlying automation assets are finding new buyers. The company recently won work connected with autonomous laboratories at Caltech, Northwestern, the University of Maryland and MIT, and it has begun work on a $47 million, 97-instrument autonomous laboratory for the Pacific Northwest National Laboratory. Its newer ADME-One service also signed 17 customers in its first six weeks, according to the company.
That mix is why using one famous company as a proxy for synthetic biology produces bad conclusions. Ginkgo's old platform model is under severe pressure at the same time that demand for DNA synthesis, automated labs and selected industrial processes is expanding.
| Company | Latest commercial evidence | Our read |
|---|---|---|
| Twist Bioscience | Revenue +23%; gene shipments +56%; DNA and protein solutions +39% | Clear growth |
| LanzaTech | Revenue rose from $9.5M to $12.0M; adjusted EBITDA loss narrowed sharply | Improving, still economically fragile |
| Ginkgo Bioworks | Revenue fell 48% to about $20M; autonomous-lab contracts are expanding | Core business still contracting while a newer infrastructure model develops |
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
Is scale-up still the biggest problem in synthetic biology?
Yes, scale-up is still the biggest problem in synthetic biology because the industry can now design biology faster than it can manufacture products cheaply and reliably.
The pattern appears across several parts of the market. A synthetic DNA supplier can ship hundreds of thousands of genes in one quarter. An autonomous laboratory can run tens of thousands of experiments. A protein model can propose huge numbers of new sequences. Industrial output has to survive feedstock costs, fermentation yields, contamination risk, downstream purification, energy use, plant utilization and customer qualification.
The U.S. government has effectively identified the same gap. The Government Accountability Office found that the Department of Defense has invested about $965 million in domestic biomanufacturing since 2021 across programs covering technology maturation, facilities and commercial-scale production.
The GAO also found that the United States lacks enough infrastructure to take promising biotechnology projects from laboratory work through pilot production and into commercial manufacturing. Pilot-scale capacity is an especially clear bottleneck. Its framework moves from roughly 1 to 100 liters in the laboratory to about 1,000 liters at pilot scale, 10,000 liters at demonstration scale and around 100,000 liters at commercial scale.
That ladder explains why so many synthetic biology companies look excellent early and then struggle. Each scale jump changes the engineering problem. A strain that performs well in a small vessel may lose productivity when oxygen transfer, mixing, temperature gradients and purification become industrial constraints.
Government money can help bridge that gap, particularly in defense where domestic supply and strategic resilience have value of their own. Private markets will ultimately demand something tougher: plants that can run at high utilization and produce goods customers repeatedly buy at sustainable margins.
For now, scale-up remains the line separating impressive synthetic biology from a large industrial market.
If you want more recent data on this point, please see our latest synthetic biology market report.
Is the synthetic biology market growing now?
Yes, the synthetic biology market is growing now, with most of the growth concentrated in tools, therapeutics and a few industrial applications.
We find enough current commercial evidence to call the market genuinely larger rather than simply more exciting scientifically. Synthetic DNA and protein tools are growing quickly. Twist's gene shipments increased 56% year over year. Commercial-scale bio-based chemical production now exists at tens of thousands of tonnes per year. Autonomous laboratories are attracting government and research customers. Large therapeutic financings continue to happen. Market estimates built from very different definitions also continue to point upward.
The weaker evidence sits in venture breadth and manufacturing economics. As seen above, our strict pure-play funding sample contains just 19 disclosed rounds and $1.01 billion over 12 months, with three companies taking 68.4% of the money. Food-fermentation funding fell about 44% in 2025. Materials companies attracted very little venture capital. Ginkgo's latest revenue fell 48%, and industrial companies still spend heavily to reach scale.
We would describe synthetic biology today as a growing market in a selective commercialization phase. The growth has become more grounded than during the previous boom because customers are now buying meaningful volumes of DNA, automated experimentation, engineered ingredients and industrial products.
The strongest businesses currently sit where synthetic biology creates an obvious economic advantage: faster research, better biological design, high-value medicines, or an existing molecule produced through a new biological process. The farther a company moves toward low-margin commodities or consumer products, the harder the economics become.
Our final judgment is clear: the synthetic biology market is growing now. It is growing unevenly, with enough real revenue, manufacturing and customer adoption to move beyond a purely speculative story. The market still has a long scale-up problem to solve, but the current evidence is stronger than a simple funding rebound and much stronger than another cycle of laboratory demos.
This chart, featured in our synthetic biology market deck, shows how gene therapy technology has evolved over time
OUR METHODOLOGY
This analysis tests whether the synthetic biology market is actually growing now by breaking the question into the parts that show real economic expansion: funding, commercial demand, customer and shipment volumes, manufacturing scale, operating economics and real-world deployment.
We did not use one market-size estimate as the answer. Published 2026 estimates range from roughly $19 billion to $32 billion because synthetic biology overlaps with biotechnology, therapeutics, fermentation, industrial biotech, engineered ingredients and research tools. We therefore use those estimates as context and give more weight to recent operating evidence.
Funding is treated carefully because taxonomy changes the result dramatically. We compare SynBioBeta's broader industry dataset with our stricter sample of publicly disclosed equity rounds involving companies where synthetic biology is central to the product or business model. Conventional biotech, basic GMOs, traditional fermentation, grants, debt and acquisitions are excluded from that narrower sample.
We also separate total capital from funding breadth. Large rounds can make the market look healthier than the typical financing environment, so we look at the median round, the share captured by the largest deals and the amount of funding left after removing unusually large financings.
Commercial growth is tested with operating data wherever possible. Twist Bioscience gives us shipment, customer, revenue and margin evidence; LanzaTech and Ginkgo Bioworks help show where commercialization remains weaker or where the business mix is changing; Qore, Pow.Bio and Bühler provide evidence on industrial-scale production rather than laboratory feasibility alone.
We use the same approach for AI and automation. The OpenAI-Ginkgo work is treated as evidence that AI can reduce experimental cost inside a controlled R&D loop, not as proof that AI has solved downstream manufacturing economics. Government and university autonomous-lab projects are used as deployment evidence rather than as a substitute for private-market demand.
Precision fermentation is assessed through both commercialization and capital. Product launches, distribution and new facilities show operating progress, while Good Food Institute investment data show that financing can still contract at the same time. That distinction is important because synthetic biology can grow operationally without producing a broad venture rebound.
Key sources used for this analysis include OECD — Synthetic Biology in Focus (https://www.oecd.org/en/publications/2025/02/synthetic-biology-in-focus_42893a6a.html), SynBioBeta — 2025 Investment Report (https://www.synbiobeta.com/reports/2025-investment-report), Twist Bioscience — Fiscal Q3 2026 Results (https://investors.twistbioscience.com/static-files/09275eee-f3b8-45a6-b39c-4201339dbc8f), OpenAI — GPT-5 Lowers the Cost of Cell-Free Protein Synthesis (https://openai.com/index/gpt-5-lowers-protein-synthesis-cost/), U.S. SEC — Ginkgo Bioworks Q2 2026 Results (https://www.sec.gov/Archives/edgar/data/1830214/000162828026053319/ex991earningspr.htm), LanzaTech — Q1 2026 Financial Results (https://ir.lanzatech.com/news-releases/news-release-details/lanzatech-reports-first-quarter-2026-financial-results), U.S. Government Accountability Office — DOD Domestic Biomanufacturing (https://www.gao.gov/products/gao-26-107797), Good Food Institute — State of the Fermentation Industry (https://gfi.org/resource/fermentation-meat-seafood-eggs-dairy-and-ingredients-state-of-the-industry/), BASF — Long-Term QIRA Supply Agreement (https://www.basf.com/cn/en/media/news-releases/global/2023/09/p306e), Pow.Bio — Continuous Fermentation Case Study (https://www.pow.bio/case-studies/case-study-power-transferability-continuous), Bühler — Pow.Bio Precision-Fermentation Partnership (https://www.buhlergroup.com/global/en/media/media-releases/pow-bio-and-buehler-join-forces-to-advance-next-generation-preci.html), NewLimit — $435 Million Series C (https://blog.newlimit.com/p/newlimit-raises-435m-led-by-founders), Profluent — $106 Million Financing (https://www.businesswire.com/news/home/20251119356889/en/Profluent-Raises-%24106M-to-Scale-Frontier-AI-Models-for-Programmable-Biology), Strand Therapeutics — Company News and Financing (https://www.strandtx.com/articles), Ansa Biotechnologies — News and Financing (https://ansabio.com/news/), and The EVERY Company — Commercial Expansion and Manufacturing Capacity (https://every.com/press-releases/every-and-huvepharma-announce-4x-production-capacity-expansion/).
In our synthetic biology market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- What does the synthetic biology startup landscape look like today?
